P7C3-A20

• Description :

  P7C3-A20 is a derivative of P7C3 with potent proneurogenic and neuroprotective activity. P7C3-A20 exerts an antidepressant-like effect. P7C3-A20 can cross the blood-brain barrier and therefore has the potential for brain injury treatment[1][2][3].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  NAMPT

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/P7C3-A20.html

• Concentration :

  10mM

• Purity :

  98.79

• Solubility :

  DMSO : ≥ 100 mg/mL

• Smiles :

  FC(CNC1=CC(OC)=CC=C1)CN2C3=CC=C(Br)C=C3C4=CC(Br)=CC=C24

• Molecular Formula :

  C22H19Br2FN2O

• Molecular Weight :

  506.21

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Blaya MO et al. Neuroprotective efficacy of a proneurogenic compound after traumatic brain injury. J Neurotrauma. 2014 Mar 1;31 (5) :476-86.|[2]Walker AK et al. The P7C3 class of neuroprotective compounds exerts antidepressant efficacy in mice by increasinghippocampal neurogenesis. Mol Psychiatry. 2015 Apr;20 (4) :500-8.|[3]Junjie Bai, et al. The Small Molecule P7C3-A20 Exerts Neuroprotective Effects in a Hypoxic-Ischemic Encephalopathy Model via Activation of PI3K/AKT/GSK3β Signaling. Neuroscience. 2020 Jun 3; S0306-4522 (20) 30353-5.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1235481-90-9]